Welcome to our dedicated page for ALK-ABELLO AS B SHS NEW news (Ticker: AKBLF), a resource for investors and traders seeking the latest updates and insights on ALK-ABELLO AS B SHS NEW stock.
ALK-Abelló AS B Shs New (symbol: AKBLF) is a leading global specialty pharmaceutical company headquartered in Hørsholm, Denmark. The company is renowned for its focus on allergy and allergic asthma treatments, offering a wide range of products and services to patients and healthcare professionals worldwide. With approximately 2,700 employees, ALK is dedicated to improving quality of life for individuals suffering from allergies.
Recently, ALK has made significant strides in broadening its reach and enhancing its product offerings with the successful acquisition of the business assets of AllerQuest, a U.S.-based company known for manufacturing PRE-PEN® (benzylpenicilloyl polylysine injection USP). PRE-PEN® is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergy, an important tool in antimicrobial stewardship and combating antibiotic resistance.
Hans Lindeberg, Senior Vice President of ALK in North America, highlighted the importance of this acquisition, emphasizing ALK's ongoing commitment to penicillin allergy testing and supporting global health initiatives, including those of the World Health Organization (WHO). The acquisition ensures ALK's role as the sole manufacturer and distributor of PRE-PEN® in the U.S. and Canada, with global ownership rights to all of AllerQuest’s assets.
In the U.S., a significant portion of the population mistakenly believes they are allergic to penicillin, leading to the use of broad-spectrum antibiotics, which can contribute to antibiotic resistance. By providing reliable diagnostic tests, ALK aims to mitigate this issue, helping patients receive appropriate treatments and reducing adverse events associated with unnecessary antibiotic use.
Financially, the acquisition is expected to strengthen ALK's position in the American market, although it is not projected to have a material impact on the company's financial results for 2024. This strategic move aligns with ALK's mission to deliver high-quality, innovative solutions for allergy management and strengthens its market presence.
For further information, ALK encourages inquiries through their Investor Relations and Media contacts at their headquarters in Denmark. Comprehensive details about ALK's products, including important safety information for PRE-PEN®, are available on their official website.
ALK, a global pharmaceutical company focused on allergy prevention, diagnosis, and treatment, has announced FDA approval for its new AccuTest™ line of allergy skin testing devices. The innovative product range includes:
1. AccuTest-1™: Single skin prick testing device
2. AccuTest-8™ and AccuTest-10™: Multi-head applicators with 8 and 10 heads respectively
3. AccuTest™ 48-well and 60-well allergen trays
These devices feature improved ergonomics, smaller tine lengths and diameters for increased accuracy and patient comfort. The allergen trays have an air-tight locking mechanism and non-slip rubber bottom for stability. A recent study suggests that AccuTest™'s lower device variability may increase result reliability compared to two currently FDA-approved skin prick tests.
ALK announced the FDA approval of ODACTRA, an allergen extract tablet for sublingual use, now indicated for treating house dust mite (HDM)-induced allergic rhinitis in individuals aged 12 to 17, alongside adults aged 18 to 65. This expands ODACTRA's use, building on its initial launch for adults in 2017. With nearly 50% of allergy patients sensitive to HDMs, this approval targets a significant market need. The 28-day MT-18 trial confirmed ODACTRA's safety and efficacy in adolescents, showing a 22% reduction in total combined rhinitis scores. This treatment offers a convenient home-administered option, enhancing allergy management for teenagers.
ALK, a global pharmaceutical company, has acquired OTIPRIO® (ciprofloxacin otic suspension) from Otonomy, Inc. This acquisition enhances ALK's presence in ear, nose, and throat (ENT) and pediatric markets. OTIPRIO is approved for treating bilateral otitis media with effusion during tympanostomy tube placements and acute otitis externa in pediatric patients. The strategic purchase follows an exclusive co-promotion agreement signed in June 2020, reinforcing ALK's aim to offer innovative healthcare solutions and expand its U.S. commercial footprint.
FAQ
What is the current stock price of ALK-ABELLO AS B SHS NEW (AKBLF)?
What is the market cap of ALK-ABELLO AS B SHS NEW (AKBLF)?
What is ALK-Abelló AS B Shs New (symbol: AKBLF)?
What recent acquisition did ALK make?
What is PRE-PEN®?
How does ALK's acquisition of AllerQuest impact its business?
Why is penicillin allergy testing important?
Who can I contact for more information about ALK?
Where can I find detailed safety information about PRE-PEN®?
What is the significance of ALK's role in antibiotic resistance?
How does ALK contribute to global health initiatives?
What products and services does ALK offer?
